Eloxatin
Diffuse Adenocarcinoma of the Stomach
University of ChicagoPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Diffuse Adenocarcinoma of the Stomach cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sargramostim National Cancer Institute (NCI) | Phase 1 | CC |
FLUOROURACILUM University of Chicago | Phase 1 | CC |
Irinotecan University of Chicago | Phase 1 | CC |
Recombinant Fowlpox-Gm-Csf National Cancer Institute (NCI) | Phase 1 | CC |
Recombinant Vaccinia-Tricom Vaccine National Cancer Institute (NCI) | Phase 1 | CC |
Recombinant Fowlpox-CEA(6D) National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →